Froodl

Statistical Analysis Plan (SAP) Development: What Should Be Finalised Before Database Lock?

Database lock is one of the most important milestones in any clinical trial. Once the database is locked, data can no longer be changed without formal unlocking procedures, and analysis begins. If the Statistical Analysis Plan (SAP) is still incomplete at this stage, the credibility of the entire study can be questioned. This is why sponsors rely on experienced clinical biostatistics services to finalise the SAP well ahead of lock.

Here is what needs to be in place before that point.

What Is a Statistical Analysis Plan?

The SAP is a detailed technical document that describes exactly how trial data will be analysed. It expands on the statistical section of the protocol and covers endpoints, analysis populations, statistical methods, handling of missing data and the format of tables, listings and figures.

Regulators expect the SAP to be finalised before unblinding, so that analysis choices are not influenced by knowledge of the results. ICH E9 and its addendum on estimands set the framework for this work.

A well-defined statistical approach also helps maintain consistency between study objectives, data collection and final analysis. Read more about clinical trial data analysis and how biostatistics supports accurate and reliable study results.

1. Clearly Defined Estimands and Endpoints

The SAP should define the primary, secondary and exploratory endpoints in precise terms. Following the ICH E9(R1) addendum, it should also describe the estimand for each key objective, including how intercurrent events such as treatment discontinuation or use of rescue medication will be handled.

Ambiguity here is one of the most common sources of disagreement between sponsors and regulators.

2. Analysis Populations

Definitions for the intent-to-treat, modified intent-to-treat, per-protocol and safety populations should be finalised. The SAP should also explain how protocol deviations will affect a patient's inclusion in each population.

3. Statistical Methods and Assumptions

Each analysis should specify the statistical model, covariates, stratification factors and significance levels. Methods for multiplicity adjustment must be clearly stated when there are multiple endpoints or treatment arms. Sensitivity analyses that test the robustness of the main results should also be pre-specified.

4. Handling of Missing Data

Missing data can bias results if not handled properly. The SAP should explain the primary approach, such as multiple imputation or mixed models, along with sensitivity analyses that test different assumptions.

5. Interim Analyses and Data Monitoring

If the study includes interim analyses, the SAP should describe their timing, purpose, stopping rules and how the overall type I error will be controlled. Responsibilities of any independent data monitoring committee should also be documented.

6. Table, Listing and Figure Shells

Mock shells for tables, listings and figures help programming teams prepare outputs in advance. Finalising these before lock reduces delays once the data becomes available.

7. Version Control and Sign-Off

The final SAP should be signed off by the sponsor and the statistical team, with a clear version history. Any changes made after unblinding must be documented and justified as post hoc.

Why Early Planning Pays Off

Strong clinical trial biostatistics starts at the protocol stage, not just before database lock. When statisticians are involved from the beginning, endpoints are better defined, data collection is designed with analysis in mind and the SAP can be drafted early and refined as the study progresses.

Sponsors working with biostatistics CRO services should look for teams that offer end-to-end biostatistics services, from sample size calculation and randomisation to SAP development, programming and clinical study report support. This continuity reduces errors and saves time.

Conclusion

A well-prepared SAP protects the integrity of a clinical trial and supports smoother regulatory review. By finalising estimands, populations, methods, missing data strategies and output shells before database lock, sponsors can move confidently into analysis. Reliable clinical research biostatistics services make this process far more manageable.

For sponsors planning their analysis strategy, Innovate Research offers a team of biostatisticians and statistical programmers whose services include sample size calculations, randomisation schedule generation and blinding and unblinding procedures. The CRO also provides clinical data management for Phase I to IV trials, keeping data handling and analysis closely aligned.

0 comments

Log in to leave a comment.

Be the first to comment.